Utility of CAML as Diagnostic for Early Stage Lung Cancer

Inclusion Criteria:

Referral for a pulmonary nodule that has not yet been biopsied and that meets the definition of an "indeterminate" nodules (i.e. 0.8-3.0 cm).
No prior diagnosis of lung cancer or other invasive malignancy within the past 5 years.
No history of rheumatologic disease.
Age > 18 years.
Ability to understand and willingness to sign a written informed consent and HIPAA consent document

Exclusion Criteria:

Patients with active, known or suspected autoimmune disease.
Prior diagnosis of lung cancer or other invasive malignancy within the past 5 years.
Uncontrolled intercurrent illness that would increase the risk of toxicity or limit compliance with study requirements. This includes but is not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the abnormal immune response that results from HIV disease (testing is not required).
Patients should be excluded if they are known to be positive for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection (testing is not required).
Subjects with any history of interstitial lung disease or a history of > or = to grade 2 radiation pneumonitis.